JAK1 and rheumatoid arthritis: Upadacitinib, an oral reversible JAK inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, and TYK2, has been approved by the U.S. FDA for treating AD, rheumatoid arthritis, and psoriatic arthritis (102).